3d printing tissue engineering scaffold advantage

Stratasys has its eyes wide open on the entire regenerative medicine field. And that the only way to set this is through 3D printing, you cannot do this with any traditional manufacturing process, you need to set the layers in the right position before you can sit together some organ or sit together real tissue behaviour that behaves exactly at the tissue in the human body. So you need to structure the cells in layers. If you put cells on a two-dimensional layer only, they fail to communicate well. In many cases, it requires just printing scaffolds, cells, stem cells, or even collagen in the right metrics in the right layers. MDN: How is 3D bioprinting going to evolve and expedite regenerative medicine?ĮBZ: 3D Bioprinting is an enabler of regenerative medicine. And these will be very patient specific because they will bypass the body’s immune response, there are non allogenic aspects to these implants or to the solutions. Soon, you will see more solutions in the research and the diagnostic or the implant scaffold solutions that will regenerate tissue, bones, or nerves. Everything must play under the same orchestra, and that’s very complex and will take more time. The heart, for instance, is the product of hundreds of millions of years of evolution including conduction systems, vessels, tissues, the entire frame. Right now we can regenerate tissue as opposed to something that is more complex. There is still an evolution of solutions to go through. Clinical studies that will improve the efficiency of the organs, as well as ethical, regulatory, operational, and legal checks before we can commercial something. It’s not all about just the technology and the materials, there are steps that we’ll have to complete before we can commercialise an organ that will replace a human organ. We require advanced technology and materials that are far beyond what is available today. MDN: Realistically, how far away is the production of human organs through biofabrication?ĮBZ: That will take us more time because to get there involves very comprehensive R&D programmes to reproduce complex organs. Producing living organs is the dream, that’s where this technology is heading, we will be able to replace organs and remove the dependency on donors. But when we talk about commercialisation, we anticipate more solutions in research and diagnostic products, so more scaffold-based solutions, more solutions that are used in research such as drug screening or tissue models that are not living organs. In the next five years, you will see more and more companies moving or transitioning from research towards the commercialisation phase. However, there are still challenges, there are steps in the process that one will have to walk. This is a huge market, and it’s growing very fast.

From 19% CAGR reaching more than $8bn in 2030. MDN: What does the next five years in bioprinting look like?ĮBZ: The bioprinting industry is growing at a very rapid pace. Also, at some point silicone implants must be replaced which requires additional surgery.

Synthetic models such as silicone implants pose the risk of rejection, leaks, or contamination. From a manufacturing perspective, it is very reproducible. The tissue heals and fills up the cavity.ĬollPlant’s plant-based collagen has great bio functionality, it allows the acceleration of human cells and their proliferation into the scaffold structure, and it promotes faster tissue healing. The scaffold is embedded with collagen that promotes the healing of the tissue, that promotes the revascularisation, and the proliferation of cells into the scaffold which then degrades within the body. Stratasys builds this breast implant layer by layer into a volumetric model that will biomechanically behave as a scaffold that promotes the growth of tissue or cells into it. This is all about regenerating, not replacing organs or tissue, it is something that creates new life within our body. Medical Device Network: How transformative could the agreement between Stratasys and CollPlant be?Įrez Ben Zvi: Regenerative medicine is disruptive and transformative to the entire industry.

3d printing tissue engineering scaffold advantage